Novo Nordisk A/S (NYSE:NVO) shares are trading higher Friday after the company announced results of an oral semaglutide trial in children aged 10-17 years old with type 2 diabetes.
- Novo Nordisk shares are climbing with conviction. What’s behind NVO gains?
Trial Results Show Significant Blood Sugar Reduction
Novo Nordisk said its phase 3a PIONEER TEENS trial demonstrated a statistically significant reduction in blood sugar levels, with HbA1c declining by 0.83% compared to placebo at 26 weeks.
The study evaluated oral semaglutide in 132 children and adolescents aged 10-17 and showed a safety profile consistent with previous semaglutide trials.
“This confirms that oral semaglutide is an effective treatment option for children and adolescents with type 2 diabetes,” said Martin Holst Lange, chief scientific officer at Novo Nordisk.
The company said the trial represents the first clinical study of an oral GLP-1 receptor agonist therapy in this age group, addressing a significant unmet need.
Novo Nordisk expects to file for regulatory approval to expand the label for oral semaglutide in the U.S. and EU in the second half of the year.
Novo Nordisk Shares Edge Higher
NVO Price Action: At the time of publication, Novo Nordisk shares are trading 3.66% higher at $39.93, according to data from Benzinga Pro.
Image via Shutterstock
Recent Comments